BioStock: Directed issue of 20.7 MSEK strengthens cash position for Sprint Bioscience
Stockholm-based Sprint Bioscience, which conducts early preclinical drug development primarily targeting cancer, announced on Thursday morning that it had raised 20.7 MSEK in a share issue directed at a group of existing and external investors. BioStock has contacted the company’s CEO Erik Kinnman to find out more about what it means for the company.Read the full article at biostock.se:https://www.biostock.se/en/directed-issue-of-20-7-msek-strengthens-cash-position-for-sprint-bioscience/This is a press release from BioStock - Connecting Innovation & Capital.https://www.biostock.se